- Home
- SNGX vs LRHC Comparison
SNGX vs LRHC Comparison
Compare SNGX & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- LRHC
- Stock Information
- Founded
- SNGX 1987
- LRHC 2004
- Country
- SNGX United States
- LRHC United States
- Employees
- SNGX N/A
- LRHC N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- LRHC
- Sector
- SNGX Health Care
- LRHC
- Exchange
- SNGX Nasdaq
- LRHC Nasdaq
- Market Cap
- SNGX 10.1M
- LRHC 8.4M
- IPO Year
- SNGX 1987
- LRHC 2023
- Fundamental
- Price
- SNGX $1.64
- LRHC $6.94
- Analyst Decision
- SNGX Strong Buy
- LRHC
- Analyst Count
- SNGX 1
- LRHC 0
- Target Price
- SNGX $6.00
- LRHC N/A
- AVG Volume (30 Days)
- SNGX 2.9M
- LRHC 12.3K
- Earning Date
- SNGX 11-07-2025
- LRHC 11-19-2025
- Dividend Yield
- SNGX N/A
- LRHC N/A
- EPS Growth
- SNGX N/A
- LRHC N/A
- EPS
- SNGX N/A
- LRHC N/A
- Revenue
- SNGX N/A
- LRHC $78,037,079.00
- Revenue This Year
- SNGX N/A
- LRHC N/A
- Revenue Next Year
- SNGX N/A
- LRHC N/A
- P/E Ratio
- SNGX N/A
- LRHC N/A
- Revenue Growth
- SNGX N/A
- LRHC 54.92
- 52 Week Low
- SNGX $1.09
- LRHC $4.33
- 52 Week High
- SNGX $6.23
- LRHC $142.40
- Technical
- Relative Strength Index (RSI)
- SNGX 41.70
- LRHC 48.78
- Support Level
- SNGX $1.60
- LRHC $6.74
- Resistance Level
- SNGX $1.97
- LRHC $7.65
- Average True Range (ATR)
- SNGX 0.16
- LRHC 0.32
- MACD
- SNGX 0.06
- LRHC -0.08
- Stochastic Oscillator
- SNGX 61.63
- LRHC 38.29
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.